stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Current ratio
GeneDx Holdings Corp.'s current ratio at the end of the quarter to 30 June 2026 was 3.3×, up 0.8× from fiscal 2025 (2.5×). Over the past ten years it has ranged from 1.5× (fiscal 2022) to 4.8× (fiscal 2021); the current reading is higher than 50% of that period. That is above the Diagnostics & Research industry median of 2.3× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.5× | (31.79%) |
| FY2024 | 3.6× | 16.49% |
| FY2023 | 3.1× | 110.39% |
| FY2022 | 1.5× | (69.14%) |
| FY2021 | 4.8× | 101.38% |
| FY2020 | 2.4× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 3.3× | 6.90% |
| Mar 2026 | 3.1× | 25.36% |
| Dec 2025 | 2.5× | (9.15%) |
| Sep 2025 | 2.7× | (5.48%) |
| 20 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| VCYT Veracyte, Inc. compare | 5.6× |
| CSTL Castle Biosciences, Inc. compare | 5.3× |
| OPK OPKO Health, Inc. compare | 5.0× |
| PSNL Personalis, Inc. compare | 4.5× |
| ADPT Adaptive Biotechnologies Corporation compare | 4.0× |
| NEO NeoGenomics, Inc. compare | 3.5× |
| WGS GeneDx Holdings Corp. | 3.3× |
| CDNA CareDx, Inc. compare | 2.3× |
| FRNM Freenome, Inc compare | 0.2× |
| Diagnostics & Research industry median | 2.3× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement